Tagged with china

China One of the largest domestic pharma companies in China (ranking number one from 2014 to 2019), Yangtze River Pharmaceutical Group (YRPG) is so-named for its location in Taizhou, Jiangsu Province, part of the Yangtze River Delta, where the Yangtze River feeds into the East China Sea. Founded initially in 1971,…

China The Chinese NMPA’s drug approval list for 2020 includes a surge in approvals for locally developed drugs. A total of 46 new drugs were approved in 2020 (less than the 53 approved in 2019), including 28 chemical drugs and 18 biological products. Read more analysis from Xu Wang of Novo…

China HiFiBiO Therapeutics cofounder, CEO and CSO Dr Liang Schweizer fits the profile of a Chinese biotech CEO to a T: advanced degrees in different scientific fields, including a master’s in microbial engineering and chemical engineering and a PhD in molecular biology and genetics, an academic career at top US institutions…

China Writing in the February edition of DIA’s Global Forum magazine, Xu Wang of Novo Nordisk Pharma China and Xiaoxi Wang from the Shanghai Center for Drug Evaluation & Inspection analyse the Chinese NMPA’s drug approval list for 2020, including a surge in approvals for locally developed drugs.   In the…

China Dr Liang Schweizer introduces immunotherapy-focused biotech HiFiBiO Therapeutics, the main advantages of the company’s unique single-cell technology platform, its open innovation approach, experience with capital markets, and advice for other biotech leaders.   The traditional bulk analysis method is well-established and suited for diseases that are more homogenous, but cancer…

China Eric Bouteiller examines the most recent update to China’s National Reimbursement Drug List, the positive impact that a de facto annual review has had on drug approval timelines, and why a more streamlined and data driven review process is positive news for the innovative pharmaceutical industry. However, Bouteiller cautions that…

China Since China first announced its ground-breaking volume-based procurement (VBP) pilot program to reduce drug expenditures in 2018, the world’s second-largest pharma market has steadily expanded the 4+7 pilot program into a regular national and provincial exercise, lopping off over a billion dollars from the top lines of both multinational and…

China 2020 has been eventful – perhaps the understatement of the year – but despite the novel coronavirus being discovered in China around the beginning of 2020, the country bounced back from the COVID-19 outbreaks by mid-year to deliver the hottest year for Chinese biopharma yet.   The Chinese biopharma sector…

China While many parts of the world ground to a halt as they tried to deal with the global pandemic, China had more or less brought the situation under control by June, and the healthcare deals engine just kept on churning. MSQ Ventures recently published its 2020 China Biopharma Global Transactions…

Global Following the recent news of Remegen’s massive USD 515 million IPO in November 2020, we bring you profiles of the seven biggest biotech companies to IPO in 2020. Notably, six of the seven companies are from China, pointing to the massive growth of the Chinese biotech market.   Remegen RemeGen,…

China The latest from Chinese pharma, including domestic regulatory approval for Sinopharm’s COVID-19 vaccine, how the country’s online healthcare industry is booming in the wake of the pandemic, and news that companies are slashing prices on new products by an average of 51 percent in order for them to be covered…

China The latest from Chinese pharma, including a drop in share prices for Chinese vaccine firms in the wake of successful COVID-19 trial results from western rivals, a new Pfizer-LianBio agreement, and Thermo Fisher’s new pharma services facility.   China pharma shares fall as western rivals lead in vaccine trials https://www.ft.com/content/c4c8453e-39f6-4aac-83a3-7d16a3f4fa4b…